GU009

Parallel phase III randomized trials for high risk prostate cancer evaluating de-intensification for lower genomic risk and intensification of concurre

Topic

GU009

Description

Primary Objective - To determine whether men with NCCN high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (< 0.85) can be treated with 12 months ADT plus RT instead of 24 months ADT+RT and experience non-inferior metastasis-free survival.

Physicians